Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Contrast Clear all
Completed Not applicable Interventional

Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound

NCT02902562
View directory record Official record
Conditions
Synovitis, Rheumatoid Arthritis
Interventions
Contrast Enhanced Ultrasound (CEUS), Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 25, 2026, 2:38 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

NCT03557385
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Iopamidol, adenosine, Navvus® Catheter, CVi® Contrast Delivery System
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Long Beach, California • Coon Rapids, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrated Behavioral Health Prevention in Pediatric Primary Care for Infants

NCT04825210
View directory record Official record
Conditions
Prevention
Interventions
Integrated Behavioral Health - Prevention, Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 25, 2026, 2:38 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy

NCT02653833
View directory record Official record
Conditions
Muscular Dystrophy
Interventions
Tadalafil 20 MG, beetroot juice extract
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 25, 2026, 2:38 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00348608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 25, 2026, 2:38 AM EDT
Withdrawn Early Phase 1 Interventional

Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity

NCT01371240
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Secretin Synthetic Human (RG1068)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

NCT03095391
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency, Chronic, Acute Kidney Injury, Urologic Diseases, Renal Insufficiency
Interventions
VFI, Iohexol
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Technical Development of up to 7T Magnetic Field Strength

NCT02666638
View directory record Official record
Conditions
Healthy
Interventions
Control Volunteers, Clinical Volunteers
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD

NCT05186415
View directory record Official record
Conditions
Tetralogy of Fallot, Pulmonary Insufficiency
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Suspended Phase 1 Interventional

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

NCT07353229
View directory record Official record
Conditions
High Risk Meningioma, Recurrent Meningioma
Interventions
⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging, MD Anderson Symptom Inventory Bain Tumor form (MDASI-BT), EuroQol-5 Dimension (ED-5D)
Radiation · Diagnostic Test · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
gadobenate dimeglumine (MultiHance)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional

The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract

NCT06365762
View directory record Official record
Conditions
Age Related Cataracts
Interventions
EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%, Saline Solution (Placebo)
Drug
Lead sponsor
Livionex Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational

MINDS Imaging Ancillary Study

NCT05270356
View directory record Official record
Conditions
Adult Congenital Heart Disease
Interventions
MRI
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 30 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 25, 2026, 2:38 AM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

NCT03023566
View directory record Official record
Conditions
Brain Diseases
Interventions
Dotarem
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 25, 2026, 2:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

NCT06151223
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI
Other · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational

Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

NCT02496260
View directory record Official record
Conditions
Breast Cancer
Interventions
Research Cardiac MRI, Biomarkers
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 25, 2026, 2:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279
View directory record Official record
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional

Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis

NCT00807729
View directory record Official record
Conditions
Choleclithiasis, Common Bile Duct Stones
Interventions
ERCP, LapCBDE
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 25, 2026, 2:38 AM EDT
Completed No phase listed Observational

Next Generation CT System

NCT06769594
View directory record Official record
Conditions
Computed Tomography
Interventions
Investigational CT Scan
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma

NCT02775786
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
MRIs with and without intravenous contrast (up to 2)
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 2:38 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

NCT05413668
View directory record Official record
Conditions
Healthy
Interventions
RVP-001, Placebo
Drug
Lead sponsor
Reveal Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 25, 2026, 2:38 AM EDT